J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 19.06 CNY -0.88% Market Closed
Market Cap: ¥15.2B

P/S

7.5
Current
13%
Cheaper
vs 3-y average of 8.6

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
7.5
=
Market Cap
¥13.9B
/
Revenue
¥2B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
7.5
=
Market Cap
¥13.9B
/
Revenue
¥2B

Valuation Scenarios

Jafron Biomedical Co Ltd is trading below its 3-year average

If P/S returns to its 3-Year Average (8.6), the stock would be worth ¥21.95 (15% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-63%
Maximum Upside
+26%
Average Downside
16%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 7.5 ¥19.06
0%
3-Year Average 8.6 ¥21.95
+15%
5-Year Average 9.4 ¥23.96
+26%
Industry Average 4.4 ¥11.23
-41%
Country Average 2.8 ¥7.05
-63%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
¥13.9B
/
Oct 2025
¥2B
=
7.5
Current
¥13.9B
/
Dec 2025
¥2B
=
7.1
Forward
¥13.9B
/
Dec 2026
¥2.3B
=
6.1
Forward
¥13.9B
/
Dec 2027
¥2.6B
=
5.4
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
CN
Jafron Biomedical Co Ltd
SZSE:300529
15.2B CNY 7.5 31.6
US
Intuitive Surgical Inc
NASDAQ:ISRG
161.2B USD 16.1 56.8
US
Abbott Laboratories
NYSE:ABT
158.6B USD 3.5 25
US
Stryker Corp
NYSE:SYK
120.5B USD 4.8 37.4
IE
Medtronic PLC
NYSE:MDT
101.9B USD 2.9 22.4
US
Boston Scientific Corp
NYSE:BSX
84.8B USD 4.1 24
US
Edwards Lifesciences Corp
NYSE:EW
47.2B USD 7.6 43.8
DE
Siemens Healthineers AG
XETRA:SHL
38.3B EUR 1.7 18.6
US
IDEXX Laboratories Inc
NASDAQ:IDXX
44.1B USD 10.4 42.3
US
Becton Dickinson and Co
NYSE:BDX
41.4B USD 1.9 24
US
Resmed Inc
NYSE:RMD
30.9B USD 5.8 20.9

Market Distribution

Higher than 79% of companies in China
Percentile
79th
Based on 7 736 companies
79th percentile
7.5
Low
0 — 1.5
Typical Range
1.5 — 5.4
High
5.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.8
70th Percentile 5.4
Max 5 034 353.9

Jafron Biomedical Co Ltd
Glance View

Market Cap
15.2B CNY
Industry
Health Care

In the heart of China's bustling Guangdong province, Jafron Biomedical Co., Ltd. has carved a distinguished niche in the world of biomedicine since its inception. This innovative company, recognized as a leader in the hemoperfusion field, has built its reputation on a foundation of pioneering blood purification technologies. By developing and manufacturing an array of hemoperfusion devices, Jafron offers critical solutions that aid in the removal of toxins from the bloodstream, thus improving outcomes for patients suffering from various systemic toxic reactions and kidney-related disorders. Their state-of-the-art hemoperfusion cartridges, meticulously designed for efficiency, are instrumental in managing and treating conditions such as chronic kidney disease and liver dysfunction. This relentless pursuit of quality is bolstered by a dedicated research division that harmonizes clinical insights with scientific innovation, ensuring Jafron stays at the forefront of clinical demand. Jafron Biomedical thrives on a robust business model that fuses direct sales with an expansive network of partnerships. This dual approach not only amplifies their market reach but also enables the company to establish solid footholds in key domestic and international markets. By collaborating with healthcare institutions and medical device distributors, Jafron ensures its products deliver critical health solutions to a broad clientele. The revenue streams are mainly anchored in the sales of its hemoperfusion products and through strategic expansions in emerging markets. As global health standards evolve and the demand for advanced medical solutions expands, Jafron is positioned to sustain its growth momentum by continually innovating in response to the global demand for efficient blood purification therapies. Through these methods, Jafron not only augments its economic footprint but also underscores its commitment to enhancing global healthcare standards.

Intrinsic Value
15.8 CNY
Overvaluation 17%
Intrinsic Value
Price ¥19.06
J
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett